Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome

Figures

• 

  Fig. 1. Current concepts of the coagulation process (reproduced with permission from De Caterina et al. [6]). ADP adenosine diphosphate, GP glycoprotein, PAR protein-activated receptor, TF tissue factor, vWF von Willebrand factor

• 

  Fig. 2. Design of the PIONEER AF-PCI trial [42]. aCreatinine clearance 30–49 mL/min: 10 mg od. bFirst dose 72–96 h after sheath removal. cASA (75–100 mg/day) plus clopidogrel (75 mg/day) (alternative use of prasugrel or ticagrelor allowed, but capped at 15%). dFirst dose 12–72 h after sheath removal. ASA acetylsalicylic acid, bid twice daily, DAPT dual antiplatelet therapy, INR international normalized ratio, NVAF non-valvular atrial fibrillation, od once daily, PCI percutaneous coronary intervention, R randomization, VKA vitamin K antagonist

• 

  Fig. 3. Design of the RE-DUAL PCI trial [30]. Non-US patients aged ≥ 80 years and Japanese patients aged ≥ 70 years were randomized to receive dabigatran 110 mg bid dual therapy or warfarin-based triple therapy in accordance with the respective product labels in these countries. aFirst dose within 120 h after PCI. bClopidogrel (75 mg od) or ticagrelor (90 mg bid) for at least 12 months after randomization. cASA ≤ 100 mg od was stopped at 1 or 3 months in patients who received bare-metal stent or drug-eluting stent implantation, respectively. ASA acetylsalicylic acid, bid twice daily, INR international normalized ratio, NVAF non-valvular atrial fibrillation, od once daily, PCI percutaneous coronary intervention, R randomization